| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Neuropathology (Drs. Davies, Wolska, and Masters), Royal Perth Hospital, Perth, Australia; the Department of Pathology (Drs. Wolska and Martins, Ms. Simms, and Dr. Masters), University of Western Australia, Nedlands, Australia; and the Center for Molecular Biology (Drs. Hilbich, Multhaup, and Beyreuther), University of Heidelberg, Heidelberg, Federal Republic of Germany.
The histologic diagnosis of Alzheimer's disease (AD) might be aided if a more sensitive marker of aberrant A4 amyloid protein deposition were available. We screened a sample of aged brains, using immunocytochemical methods to detect the A4 protein deposition, and found that, in comparison with conventional histologic techniques (silver impregnation and Congo red), immunocytochemistry is more sensitive and allows an easier demarcation between "normal" and "abnormal." If A4 protein deposition is accepted as a definitive marker for AD, then the age-related prevalence of AD increases dramatically. To what degree these prevalence rates are reflected in clinically detectable impairment of higher cortical function remains to be determined.
Address correspondence and reprint requests to Dr. Masters, Department of Pathology, University of Western Australia, Nedlands, Western Australia 6009, Australia.
Supported in part by grants from the National Health and Medical Research Council of Australia, the Alzheimer's Disease and Related Disorders Association, the Deutsche Forschungsgemeinschaft, the Bundesministerium fur Forschung und Technologie, and the Fonds der chemischen Industrie.
Presented in part at the fortieth annual meeting of the American Academy of Neurology, Cincinnati, OH, April 1988.
Received February 26, 1988. Accepted for publication in final form May 24, 1988.
This article has been cited by other articles:
|
|
 |
|
  G. Linazasoro, C. C. Rowe, V. L. Villemagne, and C. L. Masters IMAGING {beta}-AMYLOID BURDEN IN AGING AND DEMENTIA Neurology, April 29, 2008; 70(18): 1649 - 1650. [Full Text] [PDF]
|
|
|
|
 |
|
 H.-g. Lee, X. Zhu, R. J. Castellani, A. Nunomura, G. Perry, and M. A. Smith Amyloid-beta in Alzheimer Disease: The Null versus the Alternate Hypotheses J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 823 - 829. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Liang, T. Dunckley, T. G. Beach, A. Grover, D. Mastroeni, D. G. Walker, R. J. Caselli, W. A. Kukull, D. McKeel, J. C. Morris, et al. Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain Physiol Genomics, February 12, 2007; 28(3): 311 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Masters and K. Beyreuther Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the A{beta} amyloid pathway Brain, November 1, 2006; 129(11): 2823 - 2839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Religa, D. Strozyk, R. A. Cherny, I. Volitakis, V. Haroutunian, B. Winblad, J. Naslund, and A. I. Bush Elevated cortical zinc in Alzheimer disease. Neurology, July 11, 2006; 67(1): 69 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Nunomura, R. J. Castellani, H.-g. Lee, P. I. Moreira, X. Zhu, G. Perry, and M. A. Smith Neuropathology in Alzheimer's disease: awaking from a hundred-year-old dream. Sci. Aging Knowl. Environ., March 22, 2006; 2006(8): pe10 - pe10. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. J. Castellani, H.-g. Lee, G. Perry, and M. A. Smith Antioxidant protection and neurodegenerative disease: The role of amyloid-{beta} and tau American Journal of Alzheimer's Disease and Other Dementias, March 1, 2006; 21(2): 126 - 130. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Vanderstichele, G. De Meyer, N. Andreasen, V. Kostanjevecki, A. Wallin, A. Olsson, K. Blennow, and E. Vanmechelen Amino-Truncated {beta}-Amyloid42 Peptides in Cerebrospinal Fluid and Prediction of Progression of Mild Cognitive Impairment Clin. Chem., September 1, 2005; 51(9): 1650 - 1660. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. Y. Chan A New Hypothesis (Concept) of Diagnosing Alzheimer's Disease J. Gerontol. A Biol. Sci. Med. Sci., October 1, 2002; 57(10): M645 - 647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. A. Crystal, D. Dickson, P. Davies, D. Masur, E. Grober, and R. B. Lipton The Relative Frequency of "Dementia of Unknown Etiology" Increases With Age and Is Nearly 50% in Nonagenarians Arch Neurol, May 1, 2000; 57(5): 713 - 719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Andreasen, C. Hesse, P. Davidsson, L. Minthon, A. Wallin, B. Winblad, H. Vanderstichele, E. Vanmechelen, and K. Blennow Cerebrospinal Fluid {beta}-Amyloid(1-42) in Alzheimer Disease: Differences Between Early- and Late-Onset Alzheimer Disease and Stability During the Course of Disease Arch Neurol, June 1, 1999; 56(6): 673 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Marcon, G. Giaccone, B. Canciani, L. Cajola, G. Rossi, L. De Gioia, M. Salmona, O. Bugiani, and F. Tagliavini A ßPP Peptide Carboxyl-Terminal to Aß Is Neurotoxic Am. J. Pathol., April 1, 1999; 154(4): 1001 - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M Esiri, S. C Biddolph, and C. S Morris Prevalence of Alzheimer plaques in AIDS J. Neurol. Neurosurg. Psychiatry, July 1, 1998; 65(1): 29 - 33. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Lalowski, A. Golabek, C. A. Lemere, D. J. Selkoe, H. M. Wisniewski, R. C. Beavis, B. Frangione, and T. Wisniewski The "Nonamyloidogenic" p3 Fragment (Amyloid beta 17-42) Is a Major Constituent of Down's Syndrome Cerebellar Preamyloid J. Biol. Chem., December 27, 1996; 271(52): 33623 - 33631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Raskin, M. D. Applegate, D. L. Price, J. C. Troncoso, and J. C. Hedreen Comparison of New and Traditional Methods for Detection of Senile Plaques in Alzheimer's Disease J Geriatr Psychiatry Neurol, April 1, 1995; 8(2): 125 - 131. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
